For instance, studies confirm that EZH2 possesses tumorigenic properties in lymphomas (Van Kemenade et al., 2001), chronic myelogenous leukemia (CML) (Xie et al., 2016), multiple myeloma (Xu et al., 2023), natural killer/T-cell lymphoma (NKTL) (Yan et al., 2013) as well as AML. The gene discussed is EZH2; the disease is acute myeloid leukemia.